4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• The human dopamine D4 receptor (hD4) is a key target for treating various central nervous system disorders.
• Selective ligands for hD4 receptors are crucial for understanding receptor function and developing targeted therapies.
• Existing ligands often lack sufficient selectivity, leading to off-target effects.

Purpose of the Study:

• To identify and characterize novel, selective antagonists for the human dopamine D4 receptor.
• To explore structure-activity relationships (SAR) for optimizing hD4 affinity and selectivity.
• To evaluate the pharmacokinetic properties of lead compounds for potential therapeutic use.

Main Methods:

• Screening of chemical libraries to identify initial hits.
• Systematic modification of lead compounds to establish SAR.
• In vitro receptor binding assays to determine affinity and selectivity against dopamine receptor subtypes (D2, D3, D4).
• In vivo pharmacokinetic studies including oral bioavailability, half-life, and brain penetration.

Main Results:

• Compound 3 (5-(4-chlorophenyl)-3-(1-(4-chlorobenzyl)piperidin-4-yl)pyrazole) was identified as a moderate hD4 ligand with limited selectivity.
• SAR studies revealed optimal structural features, including a 4-chlorophenyl group, a 4-substituted piperidine, a phenethyl group on the piperidine nitrogen, and an isoxazole heterocycle.
• The optimized compound, 36 (5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole), demonstrated nanomolar antagonism at hD4 receptors with >500-fold selectivity over hD2 and >200-fold over hD3.
• Compound 36 exhibited good oral bioavailability (38%), a half-life of 2 hours, and significant brain penetration (10-fold higher than plasma levels).

Conclusions:

• Compound 36 represents a highly potent and selective antagonist for the human dopamine D4 receptor.
• The identified SAR provides a valuable framework for designing future hD4-targeting ligands.
• The favorable pharmacokinetic profile of compound 36 suggests its potential as a therapeutic agent for hD4-related conditions.